Neuroimmunophilin ligands exert neuroregeneration and neuroprotection in midbrain dopaminergic neurons.
Immunosuppressant drugs, like FK506, and nonimmunosuppressant compounds like, GPI1046 and L685818, are immunophilin ligands that specifically bind to immunophilins, like FK506 binding protein 12 (FKBP12). Several lines of evidence show that these ligands exert neurotrophic properties in neural injury models and in PC12 cells. However, the mechanism of the neurotrophic function of the immunophilin ligands is poorly known. In the present study, we use MPP+ and 6-OHDA toxicity models to examine both neuroprotective and neuroregenerative effects of immunophilin ligands on primary cultures of midbrain dopaminergic neurons. We find that FK506, GPI1046 and L685818 at concentrations from 0.01 to 1 microM partially, but significantly, protect dopaminergic neurons against both MPP+ and 6-OHDA toxicity. By Western blot analysis, we also find that all three compounds prevent tyrosine hydroxylase (TH) loss induced by MPP+ and 6-OHDA treatments. Morphologic analysis of dopaminergic neurons, by immunocytochemistry, shows that MPP+ and 6-OHDA cause the retraction and loss of neuronal processes, while FK506, GPI1046 and L685818 promote regeneration of these processes as indicated by increases in process number and length. To examine if FKBP12 is required for neurotrophic effects of immunophilin ligands, we cultured dopaminergic neurons from FKBP12 knockout mice and find that FK506 still protects dopaminergic neurons against MPP+ toxicity. These results suggest that FKBP12 is not essential for the neurotrophic properties of immunophilin ligands, and immunophilin ligands are a new class of neuroprotective and neuroregenerative agents that may have therapeutic potential in a variety of neurological disorders.
Guo
X
X
Department of Neurology, Johns Hopkins University School of Medicine, 600 N. Wolfe St., Carnegie 2-214, Baltimore, MD 21287, USA.
Dawson
V L
VL
Dawson
T M
TM
D015655:1-Methyl-4-phenylpyridinium / Q000494:pharmacology; D000818:Animals; D001930:Brain Injuries / Q000188:drug therapy* / Q000276:immunology / Q000503:physiopathology; D002478:Cells, Cultured / Q000187:drug effects / Q000276:immunology / Q000378:metabolism; D004298:Dopamine / Q000378:metabolism; D020104:Immunophilins / Q000187:drug effects* / Q000276:immunology / Q000378:metabolism; D007166:Immunosuppressive Agents / Q000494:pharmacology; D008024:Ligands; D008636:Mesencephalon / Q000187:drug effects / Q000276:immunology / Q000378:metabolism; D051379:Mice; D018345:Mice, Knockout; D009410:Nerve Degeneration / Q000188:drug therapy* / Q000276:immunology / Q000503:physiopathology; D009416:Nerve Regeneration / Q000187:drug effects* / Q000276:immunology; D009474:Neurons / Q000187:drug effects / Q000276:immunology / Q000378:metabolism; D018696:Neuroprotective Agents / Q000276:immunology / Q000494:pharmacology*; D009498:Neurotoxins / Q000037:antagonists & inhibitors; D016627:Oxidopamine / Q000494:pharmacology; D020734:Parkinsonian Disorders / Q000188:drug therapy / Q000276:immunology / Q000503:physiopathology; D011759:Pyrrolidines / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley; D016559:Tacrolimus / Q000031:analogs & derivatives* / Q000494:pharmacology; D022061:Tacrolimus Binding Protein 1A / Q000172:deficiency / Q000235:genetics; D014446:Tyrosine 3-Monooxygenase / Q000378:metabolism
C104949:GPI 1046; D007166:Immunosuppressive Agents; D008024:Ligands; D018696:Neuroprotective Agents; D009498:Neurotoxins; D011759:Pyrrolidines; C076383:L 685818; D016627:Oxidopamine; D014446:Tyrosine 3-Monooxygenase; D022061:Tacrolimus Binding Protein 1A; D020104:Immunophilins; D015655:1-Methyl-4-phenylpyridinium; D004298:Dopamine; D016559:Tacrolimus